ClinicalTrials.gg
TerminatedNCT02160041CBGJ398XUS04Updated Jun 18, 2019Results posted

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

A Phase 2 interventional study of BGJ398 in Solid Tumor and Hematologic Malignancies, sponsored by Novartis Pharmaceuticals. Terminated at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Hematologic Neoplasms by Novartis — 1 open to participants now, 1 under way, 1 of them phase 3. Hematologic Neoplasms · Novartis.

Enrollment
7th of 18
84 · median 49
Started
2014
with 3 others
Phase 2
9 of 18
none open now
Registered
13th of 18
by date

Among the 18 studies in Hematologic Neoplasms by Novartis, this one is the 7th largest by enrollment, is one of 4 that started in 2014, is one of 9 in phase 2, and was the 13th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

1 of the 18 studies in Hematologic Neoplasms by Novartis is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hematologic Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this signal seeking study was to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.

03

Conditions studied

  • Solid Tumor
  • Hematologic Malignancies

Keywords

  • Solid tumor malignancy
  • hematologic malignancy
  • mutation
  • translocations
  • amplifications,
  • fusions
  • signature
  • FGFR
  • ligand
  • BGJ398
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of Urothelial cell carcinoma, Cholangiocarcinoma, Endometrial cancer, and Glioblastoma multiforme) or hematologic and is in need of treatment because of progression or relapse.

Patient's tumor has been evaluated and pre-identified as having a tumor with a FGFR genetic alteration. The qualifying alteration must be assessed and reported by a CLIA-certified laboratory.

Patient must have received at least one prior treatment for recurrent, and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.

Patient must have progressive and per 1.1. or other appropriate hematological response criteria.

Patient has an (ECOG) performance status ≤ 1

Exclusion criteria

Exclusion Criteria:

Patient has received prior treatment with BGJ398

Patients with Central Nervous System (CNS) or

Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug.

Patients with acute or chronic pancreatitis

Patients with impaired cardiac function or cardiac diseases

History and/or current evidence of extensive tissue calcification

Use of medications that increase serum levels of phosphorus and/or calcium

Current evidence of corneal or retinal disorder/keratopathy

History and/or current evidence of renal or endocrine alterations of calcium/phosphate homeostasis

Patients with another primary within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    BGJ398

    BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.

    Drug: BGJ398

Interventions

  • DrugBGJ398

    BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate (CBR) Associated With BGJ398 Treatment

    Tumor Response: Overall response rate (ORR) and clinical benefit rate (CBR) for solid tumor (non-lymphoma) which excludes 3 TIO and 1 Lymphoma patients (hence 80 patients and not 84) Clinical benefit rate for patients with solid tumors were assessed using RECIST 1.1 and include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria may apply Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: 16 weeks

Secondary outcomes

  1. Overall Response (OR) or Partial Response (PR) or Greater

    The key secondary endpoint, OR, was determined by Investigator assessment for each tumor assessment and defined as responses of CR and PR per RECIST version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months

  2. Progression-Free Survival (PFS)

    Kaplan-Meier estimates of PFS timing, months Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause

    Time frame: every 8 weeks until death, assessed up to 24 months

  3. Kaplan-Meier Estimates of PFS Rate, % (95% CI)

    Time frame: Months 1, 2, 3, 4, 5, 6, 12, 18, 24

  4. Overall Survival (OS)

    Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause

    Time frame: every 8 weeks until death, assessed up to 36 months

  5. Kaplan-Meier Estimates of Survival Rate, % (95% CI)

    Overall survival (OS) is the time from the date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact.

    Time frame: months 3, 6, 9, 12, 24

  6. Number of Participants With 99 Day Minimum Duration of Response (DOR)

    The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause

    Time frame: baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months

07

Results

Posted Jun 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneBGJ398
Started84
Completed0
Not completed84
Withdrew: Adverse event11
Withdrew: Death2
Withdrew: Disease progression57
Withdrew: Protocol violation1
Withdrew: Non-compliance with study1
Withdrew: Physician decision3
Withdrew: Withdrawal by subject8
Withdrew: Study terminated by by sponsor1

Outcome measures

PrimaryClinical Benefit Rate (CBR) Associated With BGJ398 Treatment

Tumor Response: Overall response rate (ORR) and clinical benefit rate (CBR) for solid tumor (non-lymphoma) which excludes 3 TIO and 1 Lymphoma patients (hence 80 patients and not 84) Clinical benefit rate for patients with solid tumors were assessed using RECIST 1.1 and include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria may apply Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Clinical Benefit Rate (CBR) Associated With BGJ398 Treatment
ParticipantsBGJ398
Complete response (CR)0
Partial response (PR)6
Progressive disease (PD)54
Stable disease (SD)7
Non-evaluable (NE)13
Overall response rate (ORR: CR + PR)6
Clinical benefit rate (CBR: CR+PR+SD)12
SecondaryOverall Response (OR) or Partial Response (PR) or Greater

The key secondary endpoint, OR, was determined by Investigator assessment for each tumor assessment and defined as responses of CR and PR per RECIST version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months
Reported as:
Number · participants
Overall Response (OR) or Partial Response (PR) or Greater
participantsBGJ398
Overall Response (OR) or Partial Response (PR) or Greater6 (2.8 to 15.6)
SecondaryProgression-Free Survival (PFS)

Kaplan-Meier estimates of PFS timing, months Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause

Time frame:
every 8 weeks until death, assessed up to 24 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsBGJ398
Progression-Free Survival (PFS)1.8 (1.8 to 2.0)
SecondaryKaplan-Meier Estimates of PFS Rate, % (95% CI)
Time frame:
Months 1, 2, 3, 4, 5, 6, 12, 18, 24
Reported as:
Number · percent of participants
Kaplan-Meier Estimates of PFS Rate, % (95% CI)
percent of participantsBGJ398
Month 188.0 (78.2 to 93.6)
Month 238.0 (27.0 to 48.9)
Month 332.3 (21.9 to 43.0)
Month 420.0 (11.5 to 30.1)
Month 515.4 (8.0 to 24.9)
Month 612.3 (5.8 to 21.3)
Month 1210.2 (4.3 to 19.2)
Month 186.1 (1.8 to 14.5)
Month 240.0 (0.0 to 0.0)
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause

Time frame:
every 8 weeks until death, assessed up to 36 months
Reported as:
Median · months
Overall Survival (OS)
monthsBGJ398
Overall Survival (OS)6.2 (4.4 to 9.8)
SecondaryKaplan-Meier Estimates of Survival Rate, % (95% CI)

Overall survival (OS) is the time from the date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact.

Time frame:
months 3, 6, 9, 12, 24
Reported as:
Number · percent of participants
Kaplan-Meier Estimates of Survival Rate, % (95% CI)
percent of participantsBGJ398
Month 375.9 (64.9 to 83.9)
Month 650.1 (38.6 to 60.6)
Month 939.4 (28.5 to 50.1)
Month 1235.1 (24.6 to 45.8)
Month 2419.5 (10.5 to 30.5)
SecondaryNumber of Participants With 99 Day Minimum Duration of Response (DOR)

The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause

Time frame:
baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With 99 Day Minimum Duration of Response (DOR)
ParticipantsBGJ398
Number of Participants With 99 Day Minimum Duration of Response (DOR)6

Adverse events

Collected over Adverse Events (AEs) were collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to maximum of 26.6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BGJ39811/83 (13.3%)33/83 (39.8%)81/83 (97.6%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventBGJ398
SepsisInfections and infestations4/83
DyspnoeaRespiratory, thoracic and mediastinal disorders4/83
AnaemiaBlood and lymphatic system disorders3/83
NauseaGastrointestinal disorders3/83
Urinary tract infectionInfections and infestations3/83
Abdominal painGastrointestinal disorders2/83
DiarrhoeaGastrointestinal disorders2/83
DysphagiaGastrointestinal disorders2/83
Large intestinal obstructionGastrointestinal disorders2/83
VomitingGastrointestinal disorders2/83
Most frequent other events
Showing 10 of 60
Most frequent other events
EventBGJ398
HyperphosphataemiaMetabolism and nutrition disorders47/83
FatigueGeneral disorders44/83
ConstipationGastrointestinal disorders26/83
NauseaGastrointestinal disorders26/83
Dry mouthGastrointestinal disorders22/83
StomatitisGastrointestinal disorders22/83
DiarrhoeaGastrointestinal disorders20/83
Decreased appetiteMetabolism and nutrition disorders19/83
Blood creatinine increasedInvestigations17/83
DysgeusiaNervous system disorders17/83

Baseline characteristics

Full Analysis Set (FAS): The FAS included all enrolled patients who received at least 1 dose of study drug. The FAS was the primary set for efficacy analyses.

Age, Continuous
Age, Continuous(years)BGJ398
Mean60.2 ± 12.08
Age, Customized
Age, Customized(Participants)BGJ398
<65 years54
>=65-<75 years21
>=75 years9
Sex: Female, Male
Sex: Female, Male(Participants)BGJ398
Female47
Male37
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BGJ398
Caucasian74
Black6
Asian1
Other3
08

Study locations

56 sites
  • Alabama Oncology St. Vincent's Birmingham
    Birmingham, Alabama 35211, United States
  • North County Oncology Medical Clinic Inc
    Oceanside, California 92056, United States
  • San Francisco General Hospital San Francisco Gen Hosp (7)
    San Francisco, California 94110, United States
  • Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50)
    Greenwood Village, Colorado 80304, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Florida Cancer Specialists Florida Cancer Specialists 36
    Fort Myers, Florida 33901, United States
  • University of Miami Sylvester Comprehensive Cancer
    Miami, Florida 33136, United States
  • NorthWest Georgia Oncology Centers NW Georgia Oncology
    Marietta, Georgia 30060, United States
  • Harbin Clinic Medical Oncology Clin. Res.
    Rome, Georgia 30165, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • Lurie Children's Hospital of Chicago Developmental Therapeutics
    Chicago, Illinois 60611, United States
  • Community Clinical Research Center
    Anderson, Indiana 46011, United States
  • Indiana University Indiana Univ. - Purdue Univ.
    Indianapolis, Indiana 46202, United States
  • Northern Indiana Cancer Research Consortium No. Indiana Cancer Res.
    South Bend, Indiana 46617, United States
  • University of Louisville / James Graham Brown Cancer Center SC
    Louisville, Kentucky 40202, United States
  • St. Agnes Hospital St. Agnes Hospital (2)
    Baltimore, Maryland 21229, United States
  • Southcoast Centers for Cancer Care
    Fairhaven, Massachusetts 02719, United States
  • Cancer and Hematology Centers of West Michigan Dept. of Oncology
    Grand Rapids, Michigan 49546, United States
  • Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27)
    Minneapolis, Minnesota 55404, United States
  • Research Medical Center Research Med Center (2)
    Kansas City, Missouri 64132, United States
  • Billings Clinic Billings Clinic (8)
    Billings, Montana 59101, United States
  • Dartmouth Hitchcock Medical Center Dartmouth Hitchcock - Lebanon
    Bedford, New Hampshire 03110, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • New Mexico Cancer Center
    Albuquerque, New Mexico 87109, United States
  • Waverly Hematology Oncology
    Cary, North Carolina 27518, United States
  • University of N C at Chapel Hill Physician Office Building
    Chapel Hill, North Carolina 27599-7600, United States
  • Duke University Medical Center Seeley G. Mudd Bldg.
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Health Hem & Onc Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Sanford Hematology Oncology
    Fargo, North Dakota 58122, United States
  • Oncology Hematology Care Inc Oncology Hematology Care 2
    Cincinnati, Ohio 45242, United States
  • University Hospitals of Cleveland Seidman Cancer Center University Hospitals
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
  • Bend Memorial Clinic Bend Mem. Clinic
    Bend, Oregon 97701, United States
  • Northwest Cancer Specialists Northwest Cancer
    Portland, Oregon 97210, United States
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
  • Cancer Treatment Centers of America Eastern Regional Medical Center
    Philadelphia, Pennsylvania 19124, United States
  • University of Pittsburgh Cancer Institute Hillman Cancer Center (2)
    Pittsburgh, Pennsylvania 15232, United States
  • Rhode Island Hospital Rhode Island Hosp. (2)
    Providence, Rhode Island 02903, United States
  • Sanford University of South Dakota Medical Center Sanford Health
    Sioux Falls, South Dakota 57104, United States
  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology Tennessee Oncology (3)
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Oncology Consultants Oncology Group
    Houston, Texas 77024, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)
    Houston, Texas 77030, United States
  • Texas Oncology
    McAllen, Texas 78503, United States
  • Cancer Therapy & Research Center UT Health Science Center Oncology Dept.
    San Antonio, Texas 78229, United States
  • Texas Oncology Cancer Care & Research Center Texas Oncology
    Waco, Texas 76712, United States
  • Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
    Webster, Texas 77598, United States
  • Intermountain Medical Center Intermountain Healthcare
    Murray, Utah 84157, United States
  • Northern Utah Cancer Associates Northern Utah Assoc (3)
    Ogden, Utah 84403, United States
  • University of Utah / Huntsman Cancer Institute SC-2
    Salt Lake City, Utah 84103, United States
  • Utah Cancer Specialists Utah Cancer Specialists (11)
    Salt Lake City, Utah 84106, United States
  • Virginia Cancer Specialists Fairfax Northern Virginia
    Fairfax, Virginia 22031, United States
  • Shenandoah Oncology Shenandoah Oncology (5)
    Winchester, Virginia 22601, United States
  • Northwest Medical Specialties NW Medical Specialties
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Apr 2018, 45 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2014
First posted
Jun 10, 2014
StartActual
Jul 24, 2014
Primary completionActual
Apr 30, 2018
CompletionActual
Apr 30, 2018
Results first posted
Jun 18, 2019
Last update
Jun 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02160041
Responsible party
Sponsor
First posted
Jun 10, 2014
Start date
Jul 24, 2014
Primary completion
Apr 30, 2018
Completion
Apr 30, 2018
Results posted
Jun 18, 2019
Last update
Jun 18, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion